Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-20T19:05:04.506Z Has data issue: false hasContentIssue false
  • English
  • Français

Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients

Published online by Cambridge University Press:  03 January 2018

M. Franz ,
Stefanie Lis ,
K. Plüddemann  and
B. Gallhofer
M. Franz
Affiliation:
Centre for Psychiatry, Justus-Liebig University, Giessen, Germany
Stefanie Lis*
Affiliation:
Centre for Psychiatry, Justus-Liebig University, Giessen, Germany
K. Plüddemann
Affiliation:
Centre for Psychiatry, Justus-Liebig University, Giessen, Germany
B. Gallhofer
Affiliation:
Centre for Psychiatry, Justus-Liebig University, Giessen, Germany
*
Dr Michael Franz.Centre for Psychiatry, Justus-Liebig University, School of Medicine, Am Steg 22, D-3838S Giessen, Germany
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

The effectiveness of anti-psychotic drugs against positive psychotic symptoms has been demonstrated in many studies, but their effects on quality of life have yet to be clarified. The impact of different neuroleptic therapies on the subjective quality of life of schizophrenic patients is evaluated in a cross-sectional open study.

Method

During a four-month period a standardised quality of life interview for schizophrenic patients was applied on day 10 after admission; 33 patients on atypical neuroleptics (AAP) were compared with 31 matched patients on conventional neuroleptics (CAP).

Results

The AAP group had significantly higher scores in general quality of life as well as in different life domains: physical well-being, social life and everyday life. In separate comparisons of the AAP group, patients on clozapine and risperidone were found to have a higher quality of life score than patients on CAP or zotepine.

Conclusions

The pharmacological profile of clozapine and risperidone may provide a basis for explaining the higher subjective quality of life found in this study. The lower quality of life of the CAP group may possibly be related to intrinsic effects of the conventional antipsychotics.

Type
Papers
Information
The British Journal of Psychiatry , Volume 170 , Issue 5 , May 1997 , pp. 422 - 425
Copyright
Copyright © 1997 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Awad, A. G. & Hogan, T. P. (1994) Subjective response to neuroleptics and quality of life - implications for treatment outcome. Acta Psychiatrica Scandinavica, 89 (suppl. 380). 27–32.CrossRefGoogle Scholar
Dilling, H., Mombour, W. & Schmidt, M. H. (1991) Internationale Klassifikation psychischer Stórungen: ICD-10 Kapitel V(F) (ed. Weltgesundheitsorganisation, ). pp. 103–107. Bern: Huber.Google Scholar
Franz, M. & Gallhofer, B. (1996) Befindlichkeit and Compliance: Klinische Beobachtungen unter Rispendon. Therapiewoche Neurologie Psychiatrie. 10, 951–954.Google Scholar
Franz, M. & Gallhofer, B., Plüddermann, K., Gruppe, H., et al (1996) Modifikation and Anwendung der Münchner Lebensqualit?ts-Dimensionen-Liste bei schizophrenen Patienten. In Befunderhebung in der Psychiatrie: Negatrvsymptomatik. Lebensqualität and andere neue Entwicklungen (eds H. J. Möller Engel R. & P. Hoff), pp. 103–111. Vienna: Springer.CrossRefGoogle Scholar
Gelders, Y. G. (1989) Thymosthenic agents, a novel approach in the treatment of schizophrenia. British journal of Psychiatry, 155, 33–36.Google Scholar
Heinisch, M., Ludwig, M. & Bullinger, M. (1991) Psychometrische Testung der “Münchner Lebensqualitäts Dimensionen Liste (MLDL)”. In Lebensqualität bei kardiovaskulären Erkrankungen (eds M. Bollinger M. Ludwig & N. von Steinbüchel), pp. 73–90.Göttingen: Hogrefe.Google Scholar
Johnson, D. A. W. (1981) Studies of depressive symptoms in schizophrenia. The prevalence of depression and its possible causes. British journal of Psychiatry. 139, 89–101.Google Scholar
Kay, S. R., Fiszbein, A. & Opier, L. A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–275.CrossRefGoogle ScholarPubMed
Lehman, A. F. (1993) Convergent validation of quality of life assessments for persons with severe mental illnesses. Quality of Life Research. 2, 327–333.Google Scholar
Lieberman, J. A. (1993) Understanding the mechanism of action of atypical antipsychotic drugs. British journal of Psychiatry. 163 (suppl. 22). 7–18.Google Scholar
Meltzer, H.Y. (1993) Dimensions of outcome with clozapine. British journal of Psychiatry. 160 (suppl. 17), 46–53.CrossRefGoogle Scholar
Naber, D., Hacid, C., Marzeill, B., et al (1992) Zur subjektiven Wirkung von Clozapin im Vergleich zu typischen Neuroleptika. In Pharmakologie and Klinik eines atypischen Neuroleptikums (eds D. Naber & F. Müller-Spahn), pp. 171–177, Stuttgart: Schattauer.Google Scholar
Saran, A. S. (1986) Use or abuse of antiparkinsonian drugs by psychiatric patients. Journal of Clinical Psychiatry 47, 130–132.Google Scholar
Van Putten, T. & May, P. R. A. (1978) Akinetic depression in schizophrenia. Archives of General Psychiatry 35, 1101–1107.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.